<i>In vivo</i> detection of lateral–ventral tier nigral degeneration in Parkinson's disease

Huddleston, Daniel E.; Langley, Jason; Sedlacik, Jan; Boelmans, Kai; Factor, Stewart A.; Hu, Xiaoping

doi:10.1002/hbm.23547

Cited by 48 publications

(65 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar findings have been reported in previous studies using 2D NSMRI [18,20]. Recent studies by Huddleston et al [27] and Langley et al [28] have utilized in vivo detection of the lateral-ventral tier of the SNc and demonstrated the selective vulnerability of this nigral sub-region in PD. In our study, the CRs of the lateral SNc were found to correlate with the disease duration of PD.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Three‐dimensional neuromelanin‐sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease

Prasad

Stezin

Lenka

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

“…Recent studies by Huddleston et al . and Langley et al . have utilized in vivo detection of the lateral–ventral tier of the SNc and demonstrated the selective vulnerability of this nigral sub‐region in PD.…”

Section: Discussionmentioning

confidence: 90%

Three‐dimensional neuromelanin‐sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease

Prasad

Stezin

Lenka

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…33 Another recent study suggested that the in vivo assessment of neuromelanin with magnetization transfer contrast, particularly in the pSN pars compacta, might be a promising biomarker of the disease. 34 Similar to the ventral SN, PD pathology studies have also shown the pSN to be involved early and to a greater extent when compared with the aSN. 2 Using calbindin D 28K immunostaining techniques, it was demonstrated that the greatest cell loss was found in the so-called nigrosome 1 region of the SN.…”

Section: Discussionmentioning

confidence: 99%

“…Previous SN imaging studies in PD have also found larger effects to be localized to the pSN, as reported in several different modalities including DTI, neuromelanin sensitive, and QSM . Another recent study suggested that the in vivo assessment of neuromelanin with magnetization transfer contrast, particularly in the pSN pars compacta, might be a promising biomarker of the disease . Similar to the ventral SN, PD pathology studies have also shown the pSN to be involved early and to a greater extent when compared with the aSN .…”

Section: Discussionmentioning

confidence: 99%

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease

et al. 2019

View full text Add to dashboard Cite

Background Parkinson's disease (PD) is characterized in part by the progressive accumulation of iron within the substantia nigra (SN); however, its spatial and temporal dynamics remain relatively poorly understood. Objectives The objective of this study was to investigate spatial patterns and temporal evolution of SN iron accumulation in PD. Methods A total of 18 PD patients (mean disease duration = 6.2 years) receiving dopaminergic therapy and 16 healthy controls were scanned with 3T MRI at baseline and 3 years later using quantitative susceptibility mapping, an indirect marker of iron content. Iron was assessed separately in the posterior SN and anterior SN at the ventral and dorsal levels of the SN. The results were corrected for the false discovery rate. Results A significant group effect was found for the ventral posterior SN (P < .001) and anterior SN (P = .042) quantitative susceptibility mapping as well as significant group x time interaction effects (P = .02 and P = .043, respectively). In addition, a significant intragroup change during 3 years of follow‐up was found only in the ventral posterior SN of PD (P = .012), but not healthy controls. No significant effects were detected for any dorsal SN measures. No associations were identified with clinical measures. Conclusions We found both cross‐sectional and longitudinal SN iron changes to be confined to its more ventral location in PD. Because pathology studies also show the ventral SN to degenerate early and to the greatest extent in PD, the assessment of iron levels by quantitative susceptibility mapping in this area may potentially represent a disease progression biomarker in PD. © 2019 International Parkinson and Movement Disorder Society

show abstract

“…In the context of PD and other neurodegenerative diseases, previous NM imaging has consistently reported a reduction of T1 hyperintensity in the SN and LC, and a link between symptom severity and quantitative measures of neuromelanin loss . Robust normalization and quantification procedures were developed for scanner‐ and protocol‐independent data analysis as a prerequisite for multicenter trials and clinical applications . One potential limitation of these studies is the lack of detailed understanding of the physiological variation of SN pigmentation in vivo across the life span.…”

mentioning

confidence: 99%

Life span pigmentation changes of the substantia nigra detected by neuromelanin‐sensitive MRI

et al. 2018

View full text Add to dashboard Cite

Background : Neuromelanin is a pigment with strong iron‐chelating properties preferentially found in dopaminergic neurons of the substantia nigra pars compacta (SNpc). Parkinson's disease is characterized by pronounced, MRI‐detectable neuromelanin loss, but the neuroprotective or neurotoxic role of neuromelanin remains debated. Histological studies have demonstrated neuromelanin increases with age, but this has not been confirmed in vivo, and there is uncertainty whether neuromelanin declines, stabilizes, or increases from middle age. Methods : This study aimed to establish physiological changes of pigmentation of the SNpc using a pooled data set of neuromelanin‐sensitive 3T MRI from 134 healthy individuals aged 5‐83 years. Neuromelanin‐related brightness (regional contrast to ratio) and calibrated hyperintense volumes were analyzed using linear and nonlinear regression models to characterize age effects. Laterality, sex, and subregional effects were also assessed. Results : For brightness, age effects were best described as a quadratic trajectory explaining 81.5% of the observed variance in the SNpc showing a strong increase from childhood to adolescence, with plateauing in middle age and a decline in older age. Similar but less pronounced effects were seen in hyperintense volumes. We also show an anterior‐posterior gradient in SNpc contrast, larger normalized neuromelanin‐rich volume in women > 47 years old, but no laterality effect. Conclusions : Using optimized neuromelanin MRI in a life span sample, we demonstrate a strong age effect with inverted U‐shaped SNpc pigmentation‐related contrast from childhood to old age. This age trajectory of physiological SNpc pigmentation needs to be taken into account for diagnostic applications of depigmentation. The study also paves the way for systematic investigations of the mechanisms of neuromelanin in healthy and pathological brain development and aging. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

show abstract

In vivo detection of lateral–ventral tier nigral degeneration in Parkinson's disease

Cited by 48 publications

References 33 publications

Three‐dimensional neuromelanin‐sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease

Three‐dimensional neuromelanin‐sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease

Life span pigmentation changes of the substantia nigra detected by neuromelanin‐sensitive MRI

Contact Info

Product

Resources

About